John P Sfakianos1, Lan Lin Gellert2, Alexandra Maschino3, Geoffrey T Gotto1, Philip H Kim1, Hikmat Al-Ahmadie2, Bernard H Bochner4. 1. Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY. 2. Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY. 3. Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY. 4. Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY. Electronic address: bochnerb@mskcc.org.
Abstract
OBJECTIVES: The PI3k/Akt pathway has been associated with the development and progression of bladder tumors, with most studies focused on papillary or muscle-invasive tumors. We sought to characterize the expression patterns of the PI3K/Akt pathway in a large cohort of high-risk preinvasive carcinoma in situ (CIS) tumors of the bladder. Our goal was to understand whether PI3K/Akt pathway alterations associated with CIS resemble early- or late-stage bladder cancers. MATERIAL AND METHODS: We evaluated tissue specimens from 97 patients with CIS of the bladder, of which 14 had a concomitant papillary tumor. All patients were treated with intravesical bacillus Calmette-Guerin. All specimens were evaluated for PTEN, p-AKT, and p-S6 immunoreactivity. Markers were evaluated for percentage and intensity of staining and were scored using a 0 to 3+grading system. RESULTS: PTEN staining was noted as least intense in 67% of tumor specimens and 22% of normal urothelium. P-Akt and p-S6 had intense staining in 77% and 90% of tumor specimens vs. 44% and 68% in normal tissue, respectively. Low-intensity staining for PTEN at 12 months correlated with higher recurrence risk (P = 0.026). CONCLUSION: We describe a large cohort of CIS bladder tumors with decreased staining intensity of PTEN and increased staining intensity of p-AKT and p-S6, similar to high-grade and high-stage papillary tumors. Low-intensity staining of PTEN at 12 months was associated with an increased risk of recurrence.
OBJECTIVES: The PI3k/Akt pathway has been associated with the development and progression of bladder tumors, with most studies focused on papillary or muscle-invasive tumors. We sought to characterize the expression patterns of the PI3K/Akt pathway in a large cohort of high-risk preinvasive carcinoma in situ (CIS) tumors of the bladder. Our goal was to understand whether PI3K/Akt pathway alterations associated with CIS resemble early- or late-stage bladder cancers. MATERIAL AND METHODS: We evaluated tissue specimens from 97 patients with CIS of the bladder, of which 14 had a concomitant papillary tumor. All patients were treated with intravesical bacillus Calmette-Guerin. All specimens were evaluated for PTEN, p-AKT, and p-S6 immunoreactivity. Markers were evaluated for percentage and intensity of staining and were scored using a 0 to 3+grading system. RESULTS:PTEN staining was noted as least intense in 67% of tumor specimens and 22% of normal urothelium. P-Akt and p-S6 had intense staining in 77% and 90% of tumor specimens vs. 44% and 68% in normal tissue, respectively. Low-intensity staining for PTEN at 12 months correlated with higher recurrence risk (P = 0.026). CONCLUSION: We describe a large cohort of CIS bladder tumors with decreased staining intensity of PTEN and increased staining intensity of p-AKT and p-S6, similar to high-grade and high-stage papillary tumors. Low-intensity staining of PTEN at 12 months was associated with an increased risk of recurrence.
Authors: Colin P N Dinney; David J McConkey; Randall E Millikan; Xifeng Wu; Menashe Bar-Eli; Liana Adam; Ashish M Kamat; Arlene O Siefker-Radtke; Tomasz Tuziak; Anita L Sabichi; H Barton Grossman; William F Benedict; Bogdan Czerniak Journal: Cancer Cell Date: 2004-08 Impact factor: 31.743
Authors: Luciana Schultz; Roula Albadine; Jessica Hicks; Sana Jadallah; Angelo M DeMarzo; Ying-Bei Chen; Matthew E Nielsen; Matthew E Neilsen; Mark L Gonzalgo; David Sidransky; Mark Schoenberg; George J Netto Journal: Cancer Date: 2010-10-11 Impact factor: 6.860
Authors: V Stambolic; A Suzuki; J L de la Pompa; G M Brothers; C Mirtsos; T Sasaki; J Ruland; J M Penninger; D P Siderovski; T W Mak Journal: Cell Date: 1998-10-02 Impact factor: 41.582
Authors: Kyung Seok Han; In Gab Jeong; Jae Young Joung; Seung Ok Yang; Jinsoo Chung; Ho Kyung Seo; Kyung Suk Kwon; Weon Seo Park; Kang Hyun Lee Journal: Urol Int Date: 2008-05-14 Impact factor: 2.089
Authors: Christina Michailidi; Masamichi Hayashi; Sayantan Datta; Tanusree Sen; Kaitlyn Zenner; Oluwadamilola Oladeru; Mariana Brait; Evgeny Izumchenko; Alexander Baras; Christopher VandenBussche; Maria Argos; Trinity J Bivalacqua; Habibul Ahsan; Noah M Hahn; George J Netto; David Sidransky; Mohammad Obaidul Hoque Journal: Cancer Prev Res (Phila) Date: 2015-01-13
Authors: Kemal Murat Canturk; Muhsin Ozdemir; Cavit Can; Setenay Öner; Ramazan Emre; Huseyin Aslan; Oguz Cilingir; Evrim Ciftci; Fatih Mehmet Celayir; Ozgur Aldemir; Mustafa Özen; Sevilhan Artan Journal: Mol Biol Rep Date: 2014-09-05 Impact factor: 2.316
Authors: Armin Soave; Felix K-H Chun; Timo Hillebrand; Michael Rink; Lars Weisbach; Bettina Steinbach; Margit Fisch; Klaus Pantel; Heidi Schwarzenbach Journal: Oncotarget Date: 2017-05-07